HF
SYRS

HRT Financial’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

HRT Financial’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-87,535
Closed -$20K – 3602
2024
Q4 		$20K Buy
+87,535
New +$105K ﹤0.01% 2207
2024
Q2 		– Sell
-19,591
Closed -$104K – 3300
2024
Q1 		$104K Buy
+19,591
New +$135K ﹤0.01% 1852
2020
Q1 		– Sell
-1,195
Closed -$82K – 1451
2019
Q4 		$82K Buy
+1,195
New +$72.5K ﹤0.01% 1042

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

HRT Financial's SYRS Position: Q1 2025 in Review

HRT Financial sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 87,535 shares — an estimated $20K sold.

HRT Financial first reported a position in SYRS in Q4 2019 and held it in 3 quarters. The position peaked at $104K in Q1 2024. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

  • HRT Financial reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • HRT Financial sold 87,535 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $20K.
  • HRT Financial first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
  • HRT Financial's Syros Pharmaceuticals, Inc. Common Stock position peaked at $104K in Q1 2024.
  • 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on HRT Financial's 13F filing for Q1 2025, filed 15 May 2025.